The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Pegloticase Safe & Effective for Patients with Gout on Dialysis

Pegloticase Safe & Effective for Patients with Gout on Dialysis

May 19, 2021 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A recent study presented at the National Kidney Foundation’s 2021 Virtual Spring Clinical Meetings, April 6–10, found pegloticase to be safe and effective in patients with gout who are also on dialysis. Pegloticase is a pegylated recombinant form of uricase and was approved by the U.S. Food & Drug Administration (FDA) in September 2010 to treat adults with chronic gout refractory to conventional treatment.1 The treatment is a urate-oxidase enzyme that converts uric acid to allantoin, an inactive and water-soluble uric acid metabolite that is easily excreted from the body.

You Might Also Like
  • Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout
  • Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout
  • Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
Explore This Issue
June 2021
Also By This Author
  • Study Examines Why Patients Exceed Recommended Doses of Ibuprofen & NSAIDs

In the study, Bleyer et al. evaluated pegloticase in patients with uncontrolled gout who were dialysis dependent, a group not included in pre-marketing clinical trials of the agent.2 Using data from the U.S. Renal Data System (USRDS), researchers studied real-world dialysis patients with end-stage renal disease (ESRD) treated with pegloticase from 2012 to 2017. Patient characteristics and treatment parameters were evaluated.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In the five years of analyzed data, researchers identified 1,824 unique pegloticase claims, with 136 patients prescribed the treatment. Of these patients, 77 patients received pegloticase after ESRD onset, and 59 patients started pegloticase in a two-year period prior to developing ESRD. Of the 77 patients who used pegloticase post-ESRD, 42 patients had dialysis claims between 2012 and 2017 and were undergoing routine outpatient dialysis before starting pegloticase treatment. These 42 patients were evaluated in this analysis.

The Results

Patients were mostly male (76%), white (55%) and had a mean age of 53.5 ± 14.5 years. The majority of patients were between the ages of 45 and 64 (55%). The mean dialysis duration was 31.9 ± 42.9 months, with most patients receiving hemodialysis (76%), continuous cycling peritoneal dialysis (19%) or continuous ambulatory peritoneal dialysis (5%). The mean pegloticase dose was 9.7 mg, and the median interval between pegloticase doses was 14 days (mean: 19.5 days). Nine patients (21%) received at least 12 infusions.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The most common causes of ESRD in these patients were: diabetes (38%), hypertension (26%) and glomerulonephritis (17%). Their most common comorbidities upon dialysis initiation were diabetes (45%), hypertension (81.0%), congestive heart failure (24%), cerebrovascular disease (5%) and cancer (5%). Most patients had more than one comorbidity.

Ninety percent of patients were taking erythropoiesis-stimulating agents prior to starting pegloticase, while 88% of patients started taking erythropoiesis-stimulating agents after commencing pegloticase treatment. Patient hemoglobin levels were similar before and after pegloticase treatment.

The post-ESRD, office-based pegloticase prescribers were mostly rheumatologists (38%). Other office-based prescribers included hematologists, oncologists, physician assistants, pediatricians, internal medicine physicians and family practice physicians. Prescribers at outpatient dialysis facilities accounted for 58% of the post-ESRD pegloticase claims.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Conditions, Crystal Arthritis, Drug Updates Tagged With: dialysis, Gout, Gout Resource Center, pegloticaseIssue: June 2021

You Might Also Like:
  • Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout
  • Pharmacokinetics May Be Factor in Success of Pegloticase Therapy for Gout
  • Reducing Immunogenicity of Pegloticase (RECIPE) with Concomitant Use of Mycophenolate Mofetil in Patients with Refractory Gout—a Phase II Double Blind Randomized Controlled Trial
  • Treatment Options for Severe Refractory Gout When Pegloticase Fails

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)